Deceptive Advertising! Claims Novo in GLP-1 Lawsuit Fallout
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
53 articlesTwo pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
A high-profile investor move has eyes turning to a GLP-1 stock with big growth potential. Here’s what it means for ri...
A new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
A major biotech acquisition news drove a sharp move in ATAI shares. This article breaks down why ataibeckley stock so...
When a biotech deal moves a small cap, it can set the tone for the whole sector. This story explains what happened wi...
Eli Lilly stock could advance in the second half of 2026 as Foundayo gains traction and the GLP-1 franchise shines, b...
Eli Lilly sits at the center of the healthcare toolkit for many investors. This article breaks down the case for and ...
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Two drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
Investors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
Eli Lilly's blockbuster first quarter puts the spotlight on a possible stock split as its high-priced shares approach...
Eli Lilly shares surged to fresh highs, underpinned by upbeat analyst notes and strong pipeline momentum. This guide ...